Mondaca, Sebastian
Margolis, Matthew
Sanchez-Vega, Francisco
Jonsson, Philip
Riches, Jamie C.
Ku, Geoffrey Y.
Hechtman, Jaclyn F.
Tuvy, Yaelle
Berger, Michael F.
Shah, Manish A.
Kelsen, David P.
Ilson, David H.
Yu, Kenneth
Goldberg, Zoe
Epstein, Andrew S.
Desai, Avni
Chung, Vincent
Chou, Joanne F.
Capanu, Marinela
Solit, David B.
Schultz, Nikolaus
Janjigian, Yelena Y.
Funding for this research was provided by:
Conquer Cancer Foundation ASCO Career Development Award
Genetech
Article History
Received: 14 June 2018
Accepted: 30 July 2018
First Online: 7 August 2018
Compliance with ethical standards
:
: Y. Y. Janjigian has received research funding from Boehringer Ingelheim, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, and Merck and serves on advisory boards for Merck Serono, Bristol-Myers Squibb, Eli Lilly, Pfizer, and Merck.
: The present study protocol was approved by the institutional review boards at Memorial Sloan Kettering Cancer Center (MSKCC) and City of Hope Cancer Center. All patients signed written informed consent prior to study enrollment. The study was monitored quarterly by the MSKCC Data and Safety Monitoring Board and MSKCC Therapeutic Response Review Committee. This study was done in accordance with the principles of the Declaration of Helsinki.